- Products and Services
- Science & Technology
- Blog and Events
We at Sysmex Inostics recognize that one size does not fit all when it comes to next-generation sequencing solutions for oncology.
Large pan-cancer tests excel at investigation into novel markers. However, once the most relevant set of targets for a clinical application has been defined, pan-cancer testing does not make sense when only a small subset of the large panel is required.
It is also becoming increasingly clear that large NGS panels designed primarily for therapy selection do not meet the performance requirements for emerging clinical applications such as molecular monitoring of minimal residual disease using ctDNA.
Our SafeSEQ services for biopharma oncology programs bring the performance of Sysmex Inostics' OncoBEAM enhanced digital PCR technology to a unique NGS approach that prioritizes clinical relevance, quality and reliability of data, and economics.
Choose from a purpose-designed panel optimized to meet a specific clinical need, or request a rapid customization solution to ensure you have the right test for the right need.
Molecular minimal residual disease (MRD) detection via ctDNA using mutations in AKT1, APC, BRAF, CTNNB1, ERBB3, FBXW7, KRAS, NRAS, PIK3CA, POLE, PPP2R1A, RNF43, SMAD4, and TP53 as surrogate markers for disease status
SafeSEQ is customizable according to your requirements (e.g. sample type, panel design, sensitivity level) to ensure you have the most efficient test available for your clinical development program. Please contact your local Sysmex Inostics sales representative or use our contact form for more information.